BioCentury | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

...hypothalamic-pituitary-adrenal axis. Merck & Co. Inc. (NYSE:MRK) markets the dual OX1R and OX2R inhibitor Belsomra suvorexant...
...hyperarousal that keeps people awake, without the side effects of dual inhibitors. In the clinic, Belsomra...
BioCentury | May 7, 2019
Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

...Merck's Belsomra meets in AD patients with insomnia Merck & Co. Inc. (NYSE:MRK) said Belsomra suvorexant...
...baseline to week 4 vs. placebo (73.4 vs. 45.2 minutes, p<0.005) in the Phase III MK-4305-061...
...kinase receptor 1; TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2 Brian Moy, Assistant Editor ACD855 ACD856 Belsomra, suvorexant (MK-4305) Calquence...
BioCentury | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

...been antagonists of orexin receptors for indications such as insomnia. The most advanced is Belsomra suvorexant...
BioCentury | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

...been antagonists of orexin receptors for indications such as insomnia. The most advanced is Belsomra suvorexant...
BioCentury | Jul 28, 2017
Clinical News

Idorsia insomnia candidate headed for Phase III

...Co. Inc. (NYSE:MRK) markets a competitor dual orexin receptor antagonist, Belsomra suvorexant, to treat insomnia. Belsomra's...
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Orexin 2 receptor (OX2R; HCRTR2)

...with vehicle. Next steps include optimizing the sulfonamide compound. Merck & Co. Inc. markets Belsomra suvorexant...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

...OX2R antagonists target insomnia, with the most advanced being Merck & Co. Inc .'s Belsomra suvorexant...
BioCentury | Feb 16, 2015
Company News

Merck sales and marketing update

...Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor...
BioCentury | Feb 12, 2015
Distillery Therapeutics

Therapeutics: Orexin 1 receptor (HCRTR1; OX1R)

...models of psychiatric disorders. Merck & Co. Inc. markets the dual orexin receptor antagonist Belsomra suvorexant...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Inc. (NYSE:MRK) Zontivity vorapaxar Reduce thrombotic cardiovascular events U.S. Merck & Co. Inc. (NYSE:MRK) Belsomra suvorexant...
Items per page:
1 - 10 of 38